Oxford Biodynamics PLC
LSE:OBD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oxford Biodynamics PLC
LSE:OBD
|
UK |
|
Luceco PLC
LSE:LUCE
|
UK |
|
Minerva Surgical Inc
OTC:UTRS
|
US |
|
MYT Netherlands Parent BV
NYSE:MYTE
|
DE |
|
G
|
Global Health Ltd
NSE:MEDANTA
|
IN |
|
A
|
Accelera Innovations Inc
OTC:ACNV
|
US |
|
N
|
New Relic Inc
F:2NR
|
US |
|
Sparebanken Norge
F:K7I
|
NO |
|
Bank of Ningbo Co Ltd
SZSE:002142
|
CN |
|
Relief Therapeutics Holding SA
SIX:RLF
|
CH |
|
E
|
Energix Renewable Energies Ltd
TASE:ENRG
|
IL |
|
P
|
Peakstone Realty Trust
NYSE:PKST
|
US |
|
B
|
Bank of America Corp
SIX:BAC
|
US |
|
Contextlogic Inc
NASDAQ:LOGC
|
US |
|
M
|
Motherson Sumi Wiring India Ltd
NSE:MSUMI
|
IN |
|
Crown Capital Partners Inc
TSX:CRWN
|
CA |
|
Shanghai Belling Corp Ltd
SSE:600171
|
CN |
|
F
|
Fosun Tourism Group
HKEX:1992
|
CN |
|
CMO Group PLC
LSE:CMO
|
UK |
|
C
|
CSP International Fashion Group SpA
MIL:CSP
|
IT |
|
Pan Global Resources Inc
XTSX:PGZ
|
CA |
Oxford Biodynamics PLC
Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.
Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.
